In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medical technology industry invited into innovation debate:

This article was originally published in Clinica

Executive Summary

The healthcare technology industry is being encouraged to participate in the next session of the World Health Organization's Intergovernmental Working Group on Public Health, Innovation and Intellectual Property (IGWG). All interested parties have until September 30 2007 to "propose solutions aimed at fostering innovation for the creation of new products against diseases that disproportionately affect poor and marginalised populations". Contributors are asked to submit a summary of their comments (maximum 500 words) to a dedicated website (www.who.int/phi/public- hearings/second) in any of the six official UN languages - namely Arabic, Chinese, English, French, Russian or Spanish. These comments will form part of the documentation that will be discussed at the IGWG's second session, which is being hosted by the WHO during November 5-10.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT049481

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel